Copy number gain and amplification both mean extra DNA, but they are not interchangeable terms. A copy number gain is any increase above the normal diploid count, while amplification is a larger, usually focal increase that typically produces many extra copies and drives strong overexpression. The distinction is threshold-based, assay-dependent, and clinically decisive, especially in cancer testing.
The mechanism: unequal inheritance and breakage-fusion cycles
Every cell starts with two copies of each autosomal locus, one from each parent. Copy number is the measured count of those loci in a genome. A gain means the count is higher than the expected baseline; amplification means the count is high enough to imply a distinct biological process.
Most small gains arise from replication errors. During S phase, replication forks can stall at difficult sequences, and the restart machinery can re-replicate a segment. The result is a tandem duplication of perhaps a few hundred to a few thousand bases. These events are common in normal tissue and usually silent.
Amplification has different roots. One route is breakage-fusion-bridge cycling. A chromosome loses a telomere, the unprotected end fuses with its sister, and the subsequent pull apart creates a bridge that breaks. Each cycle duplicates and rearranges a segment, and repeated cycles stack many copies of the same region. Another route is extrachromosomal DNA: fragments escape the chromosome and replicate as small circular elements, sometimes dozens of copies per cell.
The distinction matters because the two processes produce different genomic architecture. Tandem gains sit in place and behave like ordinary duplications. Amplification often appears as focal, high-level peaks, sometimes on extrachromosomal circles, and frequently carries co-amplified driver genes. A 2019 analysis in Nature Genetics described extrachromosomal DNA as a distinct driver class in cancer, not merely a passive byproduct.
The practical consequence: a gain of one or two copies can be a passenger event, while a focal high-level amplification is far more likely to be selected for and to change cell behavior.
Quantified context: where the line sits
There is no universal numeric cutoff. Thresholds come from three sources: the assay's resolution, the reference genome's baseline, and the clinical guideline governing a specific test.
In germline testing, a copy number variant is usually called when a segment deviates from the expected two-copy baseline by a defined log2 ratio. Arrays can resolve events down to roughly 10 to 50 kilobases depending on probe density. Below that, gains look like noise.
In tumor sequencing, the common framework is the copy number ratio relative to the sample's own ploidy, not to two. A tumor with whole-genome duplication has a baseline of four copies, so "gain" is relative. This is where many thin explainers go wrong. A value of four copies in a diploid tumor is a gain; the same value in a tetraploid tumor is neutral.
Clinical thresholds are gene-specific and guideline-specific. For HER2 in breast cancer, the American Society of Clinical Oncology and the College of American Pathologists define positivity by immunohistochemistry score and, for equivocal cases, by in situ hybridization ratio and copy number per cell (Wolff et al., J Clin Oncol, 2018). The numeric cutoffs in that guideline are what labs apply; they differ from generic amplification definitions. For MET in lung cancer, guidelines treat high-level amplification as a distinct category with its own cutoff. For ERBB2 in gastric cancer, the criteria differ again from breast.
The lesson: the words gain and amplification describe biology, but the numbers come from the test and the disease.
| Term | Typical copy number range | Genomic pattern | Common use |
|---|---|---|---|
| Single-copy gain | 3 copies (diploid baseline) | Broad or small segment | Germline CNV, low-level tumor gain |
| Low-level gain | 3-4 copies | Broad arm-level | Tumor profiling, often passenger |
| High-level gain | 4-6 copies | Focal or broad | Borderline calls, gene-specific rules |
| Amplification | Often 6 or more, gene-specific | Focal peak, tandem or extrachromosomal | Driver calls, therapy selection |
| Polysomy | Multiple whole-chromosome copies | Whole chromosome | Distinguish from focal amplification |
| Whole-genome duplication | Roughly 4 copies genome-wide | Global | Shifts all baselines |
The ranges in this table are descriptive, not diagnostic. Confirm any clinical call against the governing guideline for that gene and tumor type.
Edge cases that break simple rules
Three situations routinely confuse interpretation. First, whole-genome duplication raises the baseline. In a tumor with four copies everywhere, a region with six copies is a modest gain, not an amplification. Analysts must estimate tumor purity and ploidy before calling anything.
Second, polysomy mimics amplification. When an entire chromosome is duplicated, the target gene's copy number rises without focal selection. Some older assays counted per-cell signals without distinguishing polysomy from true amplification, which inflated amplification rates. Modern interpretation separates the two by examining flanking regions.
Third, extrachromosomal DNA is unstable. It can be lost during cell division, so a single biopsy may undercount copies. It also clusters in micronuclei, which can be missed by some library preparations. A 2020 study in Nature Genetics linked extrachromosomal DNA to poor outcomes and to resistance, partly because it can shuffle drug targets between cells.
A counterintuitive point: more copies does not always mean more RNA or more protein. Expression depends on the promoter, chromatin state, and post-transcriptional regulation. A high copy number with intact regulatory context may overexpress; a higher copy number in silenced chromatin may not. Protein-level testing, such as immunohistochemistry, remains the anchor for several clinical decisions, which is why HER2 scoring still begins with protein.
Misconceptions worth correcting
Several beliefs circulate in summary articles and should be discarded.
Treating gain and amplification as synonyms. They differ by magnitude, mechanism, and clinical meaning; only one is a recognized driver class in most guidelines. Assuming a fixed copy number cutoff works across genes. HER2, MET, and EGFR amplification each have distinct criteria, and the criteria differ by tumor type. Ignoring tumor purity. Low-purity samples dilute tumor signal; a true amplification can be called neutral in a sample that is mostly normal tissue. Reading tumor copy number against a two-copy baseline. Ploidy correction is mandatory in tumor analysis. Assuming immunohistochemistry and copy number always agree. Discordance occurs, and guidelines specify which method governs when results conflict. Treating a gain as proof of selection. Many gains are passengers carried along by nearby driver events.
Plainly: a copy number number without context is not a diagnosis.
Practical actions for interpreting a result
Whether you are reading a report or reviewing a case, a sequence of checks reduces error. These are professional workflows, not patient instructions.
Identify the baseline. For germline tests, confirm the expected two-copy reference. For tumor tests, confirm the estimated ploidy and tumor purity. Classify the event. Decide whether the change is broad (arm- or chromosome-level) or focal (small, high-peak). Broad gains are less likely to be selected drivers. Map the magnitude. Note the absolute copy number and the ratio to the sample's baseline. Values that sit near a guideline boundary should be flagged, not forced. Check the governing guideline. HER2 breast, ERBB2 gastric, and MET lung each use different rules. Apply the one for the disease. Cross-check orthogonal methods. Compare sequencing calls with in situ hybridization or immunohistochemistry where the clinical decision depends on it. Record uncertainty. Report purity, assay limits, and any borderline classification.
Warning flags:
A reported amplification value that matches the sample's ploidy baseline. An amplification call made without tumor purity assessment. Discordance between protein and copy number that is not reconciled. A focal peak with no plausible driver gene nearby. A borderline value reported without the guideline applied.
How the call unfolds over time
Interpretation is not a single moment; it is a sequence, and errors compound when steps are skipped.
| Stage | What happens | What can go wrong |
|---|---|---|
| Specimen collection | Tissue or blood is obtained | Low tumor content, necrosis |
| Library preparation | DNA is fragmented and amplified | Coverage bias, missed circles |
| Sequencing and alignment | Reads map to reference | Reference mismatch, repeats |
| Copy number estimation | Ratios computed against baseline | Wrong ploidy assumption |
| Segmentation | Breakpoints called | Over- or under-segmentation |
| Classification | Gain or amplification assigned | Guideline misapplied |
| Reporting | Result tied to interpretation | Uncertainty omitted |
Each row is a chance to lose information. The classification step is where the gain-versus-amplification decision is actually made, and it depends on every row above it.
Limitations and what remains uncertain
The definitions are stable, but the numbers are not universal. Cutoffs shift with assay design, reference genome version, and disease-specific evidence. A cutoff that is correct for one tumor type may be wrong for another. Guidelines update; the underlying biological distinction does not.
Another limit is resolution. Short-read sequencing struggles with repetitive regions and with extrachromosomal elements. Long-read platforms improve this, but availability varies. Blood-based testing adds its own uncertainty because circulating tumor DNA fraction fluctuates.
Finally, the field lacks a single harmonized vocabulary across labs. Some reports use "gain" for any increase and reserve "amplification" for a guideline-defined category; others use the terms loosely. Until reporting standards converge, the reader must check the assay's definitions, not just the words.
The core answer stands: a copy number gain is any increase above baseline, and amplification is a larger, often focal increase that implies selection and carries clinical weight. The distance between those two ideas is measured in copies, in ploidy, and in the guideline you apply.